RNA vaccines
Patent Information
- Application Number
- HK62026124814
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-26
- Filing Date
- 2026-06-15
- Publication Date
- 2026-09-11
Smart Images

Figure 00000138_0000 
Figure 00000139_0000 
Figure 00000139_0001
Abstract
Description
Abstract This invention relates to an RNA-containing vaccine composition for inducing an immune response in subjects against Porphyromonas gingivalis, and its use therein.
Claims
1005272698126 CLAIMS 1. An RNA polynucleotide encoding a protein comprising or consisting of: - one or more amino acid sequences of an active site of an Arg- or Lys- gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and / or - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto. wherein the polynucleotide is capable of being translated in a mammalian cell.
2. The RNA of claim 1, wherein the protein encoded by the RNA comprises or consists of: - one or more amino acid sequences of an active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto.
3. The RNA of claim 1 or 2 wherein the protein encoded by the RNA polynucleotide further comprises: - the amino acid sequence of a DUF2436 domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto.
4. The RNA of any one of the preceding claims, wherein the protein encoded by the RNA polynucleotide is a chimeric or fusion protein comprising or consisting of: - one or more amino acid sequences of an active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto.1005272698127 5. The RNA of any one of the preceding claims, wherein the RNA encodes an amino acid sequence of an active site of an Arg-gingipain of P. gingivalis comprising the amino acid sequence of SEQ ID NO: 38 (eg encoded by the RNA sequence as set forth in SEQ ID NO: 50), or a sequence at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 98%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical thereto.
6. The RNA of any one of the preceding claims, wherein the RNA encodes an amino acid sequence of an active site of a Lys-gingipain of P. gingivalis comprising the amino acid sequence of SEQ ID NO: 8, (eg encoded by the RNA sequence as set forth in SEQ ID NO: 43), or a sequence at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 98%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical thereto.
7. The RNA of any one of the preceding claims, wherein the RNA encodes a chimeric or fusion protein that comprises: i) an amino acid sequence that comprises or consists of an amino acid sequence of the active site of an Arg-gingipain of P. gingivalis, or sequences that are at least 80% identical thereto; and ii) an amino acid sequence that comprises or consists of an amino acid sequence of the active site of a Lys-gingipain of P. gingivalis, or sequences that are at least 80% identical thereto.
8. The RNA of any one of the preceding claims wherein the RNA encodes a chimeric or fusion protein that comprises at least two amino acid sequences that comprise or consist of an amino acid sequence of the active site of an Arg- or Lys- gingipain of P. gingivalis, or sequences that are at least 80% identical thereto.
9. The RNA of claim 8, wherein the at least two amino acid sequences are located contiguously in the chimeric or fusion protein.1005272698128 10. The RNA of claim 8, wherein one of the at least two amino acid sequences is located at the N terminus of the chimeric or fusion protein and the second of the at least two amino acid sequences is located at the C-terminus of the chimeric or fusion protein.
11. The RNA of claim 8, wherein one of the at least two amino acid sequences is located at the N or C terminus of the chimeric or fusion protein and the second of the at least two amino acid sequences is located within the chimeric or fusion protein.
12. The RNA of claim 8, wherein the at least two amino acid sequences are (both) located at the N terminus of the chimeric or fusion protein or the at least two amino acid sequences are (both) located at the C-terminus of the chimeric or fusion protein.
13. The RNA of any one of claims 4 to 12, wherein the chimeric or fusion protein encoded by the RNA polynucleotide further comprises: - the amino acid sequence of a DUF2436 domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto.
14. The RNA of claim 13, wherein the RNA encodes: - one or more amino acid sequences of an active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and wherein the amino acid sequence of a DUF2436 domain is located between an amino acid sequence of an active site of the gingipain of P. gingivalis and the amino acid sequence of the or more adhesin binding motifs (ABMs).
15. The RNA of claim 13 or 14, wherein RNA encodes an amino acid sequence of a DUF2436 domain of an Arg or Lys gingipain of P. gingivalis comprising or consisting of the amino acid sequence of SEQ ID NO: 35, (eg encoded by the RNA sequence as set forth in SEQ ID NO: 50), or a sequence at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 98%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical thereto.1005272698129 16. The RNA of any one of claims 13 to 15, wherein the RNA encodes a substitution of a cysteine residue in the DUF2436 domain, such as a substitution to a serine or valine residue.
17. The RNA of claim 16, wherein the RNA encodes an amino acid sequence of a DUF2436 domain comprising a cysteine to serine substitution (such as shown in SEQ ID NO: 36).
18. The RNA of any one of the preceding claims wherein the RNA encodes one or more adhesin binding motifs (ABMs) comprising or consisting of the amino acid sequence of ABM2 and ABM1.
19. The RNA of claim 18, wherein the RNA encodes the amino acid sequence of a polypeptide comprising ABM2 and ABM1 as set forth in SEQ ID NO: 22 and SEQ ID NO: 21, respectively, or comprising the amino acid sequence as set forth in SEQ ID NO: 24 (ABM2+1), or a sequence at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 98%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical thereto.
20. The RNA of claim 19, wherein the RNA comprises the nucleotide sequence as set forth in any one of SEQ ID NOs: 52 to 55.
21. The RNA of any one of claims 18 to 20, wherein the RNA encodes one or more adhesin binding motifs (ABMs) comprising or consisting of the amino acid sequence of ABM2, ABM1 and ABM3.
22. The RNA of claim 21, wherein the RNA encodes the amino acid sequence as set forth in SEQ ID NO: 25 (eg encoded by an RNA comprising the sequence of SEQ ID NO: 56).
23. The RNA of any one of claims 18 to 22, wherein the RNA encodes one or more adhesin binding motifs comprising one or more modifications selected from: a) one or more cysteine amino acid substitutions compared to the naturally occurring Arg- or Lys-gingipain sequences in corresponding regions;1005272698130 b) substitution of the proline and / or an asparagine residues in the sequence PxxN corresponding to, or at a position equivalent to, residues 6 to 9 of the sequence of SEQ ID NO: 21 (ABM1); c) substitution of the motif NxFA to SxYQ in the sequence, corresponding to, or at a position equivalent to residues 2 to 5 of the sequence of SEQ ID NO: 21 (ABM1); d) substitution of the second tyrosine residue, corresponding to or at a position equivalent to residues at position 5 of SEQ ID NO: 22 (ABM2), and of the tryptophan residue, corresponding to or at a position equivalent to residue at position 23 of SEQ ID NO: 21 (ABM1) to alanine residues.
24. The RNA of claim 23, wherein the RNA encodes one or more adhesin binding motifs comprising a substitution of one or more cysteine residues to a serine residue or to a valine residue.
25. The RNA of claim 24, wherein the RNA encodes one or more adhesin binding motifs that comprise substitution of all cysteine residues to serine or valine residues.
26. The RNA of any one of claims 23 to 25, wherein the RNA encodes one or more adhesin binding motifs that comprise a proline and / or asparagine substitution of the motif PxxN (eg PVQN, SEQ ID NO: 106), corresponding to or at a position equivalent to residues 6 to 9 of SEQ ID NO:
21.
27. The RNA of claim 26, wherein the proline amino acid substitution is a substitution to an alanine residue.
28. The RNA of claim 26 or 27, wherein the asparagine amino acid substitution is a substitution to a proline residue or an alanine residue.
29. The RNA of any one of claims 23 to 28, wherein the RNA encodes one or more adhesin binding motifs comprising a substitution from PxxN to AxxP, (eg AVQP, SEQ ID NO: 107) in the region encoding the ABM1 (such as exemplified in the amino acid sequences of SEQ ID NOs: 30 to 32).
30. The RNA of any one of claims 23 to 29, wherein the RNA encodes one or more adhesin binding motifs that comprise the amino acid sequence as set forth in any one of SEQ ID NOs: 21 to 25, and comprising:1005272698131 a) one or more cysteine amino acid substitutions compared to the naturally occurring Arg- or Lys-gingipain sequences in corresponding regions, preferably substitution of all cysteine residues; and b) substitution of the motif PxxN corresponding to, or at a position equivalent to, residues 6 to 9 of the sequence of SEQ ID NO: 21 (ABM1), to AxxP.
31. The RNA of claim 30, wherein the RNA encodes one or more adhesin binding motifs comprising or consisting of the amino acid sequence as set forth in any one of SEQ ID NOs: 26 to 34, or sequences at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 98%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical thereto, provided that the sequences comprise the aforementioned substitutions of the cysteine and proline and asparagine residues.
32. An RNA polynucleotide encoding a chimeric or fusion protein comprising or consisting of: - one or more amino acid sequences of active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, 33. The RNA of claim 32, wherein the RNA encodes a chimeric or fusion protein comprising or consisting of the amino acid sequence of SEQ ID NO: 18 or 83 or SEQ ID NO: 39 or 81, or SEQ ID NO: 58 to 63, or SEQ ID NO: 82 to 87.
34. An RNA polynucleotide encoding a chimeric or fusion protein comprising or consisting of: - one or more amino acid sequences of active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; - the amino acid sequence of a DUF2436 domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, and1005272698132 - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto.
35. The RNA of claim 34, wherein the RNA encodes a chimeric or fusion protein comprising or consisting of the amino acid sequence of the amino acid sequence of SEQ ID NO: 12, 16 or 20.
36. The RNA of claim 34, wherein the RNA encodes a chimeric or fusion protein comprising or consisting of the amino acid sequence of SEQ ID NO:
4.
37. An RNA polynucleotide encoding a chimeric or fusion protein comprising or consisting of: - the amino acid sequence of a DUF2436 domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, and - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto.
38. The RNA of claim 37, wherein the RNA encodes a chimeric or fusion protein comprising or consisting of the amino acid sequence of SEQ ID NO:
14.
39. An RNA polynucleotide encoding a chimeric or fusion protein comprising or consisting of: - one or more amino acid sequences of active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and - the amino acid sequence of a DUF2436 domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto.
40. The RNA of claim 39, wherein the RNA encodes a chimeric or fusion protein comprising or consisting of the amino acid sequence of SEQ ID NO: 10 or 108.
41. An RNA polynucleotide encoding a chimeric or fusion protein comprising or consisting of:1005272698133 - one or more amino acid sequences of active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; - the amino acid sequence of a DUF2436 domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, and - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto.
42. The RNA of claim 41, wherein the RNA encodes a chimeric or fusion protein comprising or consisting of the amino acid sequence of SEQ ID NO:
6.
43. An RNA polynucleotide comprising or consisting of a nucleotide sequence encoding a protein comprising or consisting of the amino acid sequence of any one of: SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO:
38.
44. An RNA comprising or consisting of a nucleotide sequence of any one of: a) SEQ ID NO: 48, 57, b) SEQ ID NO: 45, 47 or 49 or SEQ ID NO: 41; c) SEQ ID NO: 46; d) SEQ ID NO: 44; e) SEQ ID NO:
42.
45. An RNA comprising or consisting of a nucleotide sequence of any one of: SEQ ID NO: 40, SEQ ID NO: 43 or SEQ ID NO:
50.
46. The RNA of any one of the preceding claims, wherein the RNA is an mRNA.
47. The RNA of any one of the preceding claims wherein the RNA further encodes an N-terminal signal peptide for enabling secretion of the protein following translation thereof.
48. The RNA of any one of the preceding claims, wherein the RNA further comprises a 5’ untranslated region (UTR) and / or a 3’ UTR.1005272698134 49. The RNA of any one of the preceding claims, wherein the RNA also comprises a 5’ cap analog, such as 7mG(5′)ppp(5′)NlmpNp.
50. The RNA of any one of the preceding claims wherein the RNA also comprises a polyadenine (polyA) tail.
50. The RNA of any one of the preceding claims, wherein the RNA comprises a chemical modification, preferably wherein the chemical modification is a 1- methylpseudouridine modification or a 1-ethylpseudouridine modification.
52. The RNA of any one of the preceding claims wherein the RNA has a uridine content of less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20% or less than about 15%.
53. The RNA of any one of the preceding claims, wherein the uridines in the RNA are replaced with a chemical modification such as N-methyl-pseudouridine.
54. The RNA of claim 53, wherein at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of the uridine nucleosides are replaced with N-methyl-pseudouridine.
55. The RNA of any one of the preceding claims wherein the RNA is in the form of a codon optimised RNA molecule.
56. A composition comprising an RNA of any one of the preceding claims.
57. A lipid nanoparticle composition comprising an RNA of any one of claims 1 to 55.
58. The lipid nanoparticle composition of claim 57, comprising: - a cationic and / or ionisable lipid comprising from about 25 % to about 75 mol % of the total lipid present in the nanoparticle; - a sterol (structural lipid) comprising from about 5 mol % to about 60 mol % of the total lipid present in the nanoparticle;1005272698135 - a phospholipid comprising from about 5 mol % to about 50 mol % of the total lipid present in the nanoparticle; - a PEGylated lipid comprising from about 0.5 mol % to 20 mol % of the total lipid present in the nanoparticle.
59. The lipid nanoparticle composition of claim 57 or 58, comprising: - an ionisable lipid in the form of [(4-hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2-hexyldecanoate) (ALC-0315), - a sterol in the form of cholesterol, - a phospholipid in the form of distearoylphosphatidylcholine (DSPC), and - a PEGylated lipid in the form of 2-[(polyethylene glycol)-2000]-N,N- ditetradecylacetamide (ALC-0159).
60. The lipid nanoparticle composition of claim 59, wherein the lipids are present in the lipid nanoparticle at molar lipid ratios (%) of 46.3 ALC-0315: 42.7 cholesterol : 9.4 DSPC : 1.6 ALC-0159, optionally in Tris / sucrose buffer (25 mM Tris pH 7.4, 8.8% sucrose w / v).
61. A method for producing a lipid nanoparticle comprising an RNA of any one of claims 1 to 55, wherein preferably the method comprises formulating any RNA molecule of any one of claims 1 to 55, with one or more lipids useful for producing a lipid nanoparticle.
62. The method of claim 61, wherein the lipid components comprise a phospholipid, a PEG lipid, and a structural lipid.
63. A nucleic acid construct or vector, comprising an RNA polynucleotide of any one of claims 1 to 55.
64. A method for eliciting an immune response P. gingivalis in a subject in need thereof, the method comprising administering to the subject, an RNA of any one of claims 1 to 55 or a nanoparticle or composition of any one of claims 56 to 60.1005272698136 65. A method for eliciting an immune response to P. gingivalis in a subject in need thereof, the method comprising administering to the subject, a nanoparticle composition comprising: - an RNA of any one of claims 1 to 55, - an agent for enabling delivery of the RNA to a cell of the subject; - wherein said RNA is capable of being translated in a cell of the subject to produce the polypeptide encoded by the polynucleotide.
66. A method for producing a chimeric or fusion protein in a mammalian cell, the method comprising contacting the mammalian cell with a nanoparticle composition, the composition comprising: - an RNA of any one of claims 1 to 55, - an agent for enabling delivery of the RNA to a cell of the subject; - wherein said RNA is capable of being translated in the mammalian cell to produce the protein.
67. A method for delivering an RNA to a mammalian cell in a subject in need thereof, said method comprising administering to a subject in need thereof, a nanoparticle composition, the composition comprising: - an RNA comprising a polynucleotide sequence of any one of claims 1 to 55, - an agent for enabling delivery of the RNA to a cell of the subject; - wherein said RNA is capable of being translated in the mammalian cell to produce the chimeric or fusion protein described herein; wherein the administering comprises contacting said mammalian cell with the nanoparticle composition, thereby enabling delivery of the RNA to the mammalian cell.
68. The method of any one of claims 65 to 67, wherein the agent for enabling delivery of the RNA to a cell of the subject is a lipid.1005272698137 69. The method of claim 68, wherein the lipid comprises a cationic and / or ionisable lipid, a phospholipid, a PEG lipid, and a structural lipid.
70. Use of an RNA of any one of claims 1 to 55, or a vector, or nanoparticle comprising the same, in the manufacture of a composition for eliciting an immune response to P. gingivalis in a subject.
71. Use of i) a lipid component, preferably comprising a cationic and / or ionisable lipid, a phospholipid, a PEG lipid, and a structural lipid., and ii) an RNA of any one of claims 1 to 55, in the manufacture of a composition for delivering the RNA to a mammalian cell in a subject in need thereof.
